Tonix Pharmaceuticals | ARS: Annual Report to Security Holders
Apr 15 16:50 ET
Tonix Pharmaceuticals | DEF 14A: Definitive information statements
Apr 15 16:40 ET
Tonix Pharmaceuticals | PRE 14A: Preliminary proxy statements relating to merger or acquisition
Apr 5 16:50 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
Apr 1 16:43 ET
Tonix Pharmaceuticals | 10-K: Annual report
Apr 1 16:40 ET
Tonix Pharmaceuticals | 424B5: Prospectus
Mar 29 17:33 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering
Mar 29 17:19 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome
Mar 25 09:08 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting
Mar 21 09:26 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia
Mar 20 09:52 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024
Mar 19 08:06 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Holding Corp. Announced the Presentation of Additional Efficacy Data from the Phase 3 Resilient Study
Mar 11 08:06 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime Tnx-102 Sl on Ptsd Symptoms and Sleep Quality in Military-Related Ptsd at Four Weeks of Therapy
Mar 7 08:09 ET
Tonix Pharmaceuticals | 4/A: Statement of changes in beneficial ownership of securities (and amendment thereto)-Officer LEDERMAN SETH
Mar 6 17:06 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia
Mar 6 08:08 ET
Tonix Pharmaceuticals | 8-K: Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans
Mar 5 08:07 ET
Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer LEDERMAN SETH
Feb 29 17:15 ET
Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SAENGER BRADLEY
Feb 29 17:14 ET
Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer SULLIVAN GREGORY M
Feb 29 17:10 ET
Tonix Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer MORRIS JESSICA EDGAR
Feb 29 17:10 ET
No Data
No Data